COMPARISON
Bacitracin vs Colistin
3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.
Answer
Bacitracin is authorised or registered in 8 and Colistin in 7 of the 10 registers read. Bacitracin: No trial states a phase. Colistin: highest phase Phase 4 (after approval). 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Bacitracin | Colistin | |
|---|---|---|
| Registered trials differs | 53 clinicaltrials.gov · 2026-10-03 | 130 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA label, not an approval: health and .beyond Triple Antibiotic openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Cortisporin TC openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Nothing on record ema read 2026-08-31 | Nothing on record ema read 2026-08-31 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Bacitracin | placebo | Colistin | placebo |
|---|---|---|---|---|
| Acute kidney injury | - | - | 30.3% | 33.9% |
| Creatinine increased | - | - | 20.2% | 23.5% |
| Sepsis | - | - | 9.6% | 10.4% |
| Aspartate aminotransferase increase | - | - | 4.4% | 5.7% |
| Hypokalemia | - | - | 4.4% | 4.8% |
| Aspartate aminotransferase increased | - | - | 3.9% | 3.5% |
| Blood bilirubin increased | - | - | 3.9% | 5.7% |
| ALT increased | - | - | 3.1% | 1.3% |
| Anemia | - | - | 2.6% | 5.2% |
| Hypoalbuminemia | - | - | 2.2% | 3.9% |
Trial register Bacitracin: 0 placebo-controlled trials; Colistin: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Bacitracin side effects · Colistin side effects
LEGAL STATUS
Approval in each country read
| Country | Bacitracin | Colistin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Status unknown | Status unknown | TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT02099240 | Patients Response to Early Switch To Oral:Osteomyelitis Study TERMINATED · updated 2021-04-06 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.